AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Mucus plugs affect some 40% to nearly 70% of COPD patients, and even clinically silent mucus plugs are linked to poorer ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Vaping is especially popular among teenagers and young adults, but fruity, candy-like flavours come with a chemical cost ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

For World Asthma Day, GINA released its 2025 guidelines update and joined in a campaign to make inhaled asthma therapies more ...

Discover when coughing up blood requires emergency medical care. Learn the causes, warning signs, and critical first steps ...

With lung tumour cases on the rise in India, robotic-assisted thoracic surgery offers a breakthrough—providing faster ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Ariel Lopez-Chavez, MD, medical oncologist, director of precision medicine and developmental therapeutics at Allegheny Health Network Cancer Institute, discusses comprehensive genomic profiling and ...

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...